{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=penicillamine", "query": { "intervention": "penicillamine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=penicillamine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T08:48:53.339Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03403205", "title": "Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wilson Disease" ], "interventions": [ { "name": "ALXN1840", "type": "DRUG" }, { "name": "SoC Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 214, "start_date": "2018-02-22", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2024-06-17", "last_synced_at": "2026-09-07T08:48:53.339Z", "location_count": 6, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03403205" }, { "nct_id": "NCT07301216", "title": "Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Wilson Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-01-08", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-07T08:48:53.339Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07301216" }, { "nct_id": "NCT05783687", "title": "Real World Evidence Study in Subjects With Wilson's Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Wilson Disease" ], "interventions": [ { "name": "NCC-Sp Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Orphalan", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-06-28", "completion_date": "2025-09-12", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-09-07T08:48:53.339Z", "location_count": 9, "location_summary": "Sacramento, California • New Haven, Connecticut • Miami, Florida + 6 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05783687" }, { "nct_id": "NCT02125721", "title": "Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cystinuria" ], "interventions": [ { "name": "Tiopronin 1g per day", "type": "DRUG" }, { "name": "Tiopronin 2g per day", "type": "DRUG" }, { "name": "Tiopronin 3g per day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 10, "start_date": "2012-06", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2021-08-23", "last_synced_at": "2026-09-07T08:48:53.339Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02125721" }, { "nct_id": "NCT03106948", "title": "Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arteriovenous Fistula Occlusion" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Cuprimine Oral Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Southeast Renal Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 30, "start_date": "2017-02-01", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2017-09-11", "last_synced_at": "2026-09-07T08:48:53.339Z", "location_count": 1, "location_summary": "Chattanooga, Tennessee", "locations": [ { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03106948" }, { "nct_id": "NCT02763215", "title": "The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Wilson Disease" ], "interventions": [ { "name": "Standard of Care Medications", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2016-05-19", "completion_date": "2019-01-21", "has_results": true, "last_update_posted_date": "2020-12-01", "last_synced_at": "2026-09-07T08:48:53.339Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02763215" }, { "nct_id": "NCT07465718", "title": "Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wilson's Disease" ], "interventions": [ { "name": "TETA 4HCl formulation", "type": "DRUG" }, { "name": "D-Penicillamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orphalan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 38, "start_date": "2026-08", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-07T08:48:53.339Z", "location_count": 3, "location_summary": "Denver, Colorado • New Haven, Connecticut • Ann Arbor, Michigan", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07465718" }, { "nct_id": "NCT03539952", "title": "Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wilson Disease" ], "interventions": [ { "name": "Penicillamine (D1-W12)", "type": "DRUG" }, { "name": "TETA 4HCL (W12-60)", "type": "DRUG" }, { "name": "Penicillamine (W12-W60)", "type": "DRUG" }, { "name": "TETA 4HCL (60-